141.35
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$142.37
Offen:
$141.84
24-Stunden-Volumen:
1.11M
Relative Volume:
0.78
Marktkapitalisierung:
$20.60B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.62B
KGV:
12.77
EPS:
11.07
Netto-Cashflow:
$1.77B
1W Leistung:
-1.79%
1M Leistung:
-7.70%
6M Leistung:
-29.25%
1J Leistung:
-41.24%
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
BIIB
Biogen Inc
|
141.35 | 20.60B | 9.61B | 1.62B | 1.77B | 11.07 |
![]()
LLY
Lilly Eli Co
|
878.31 | 834.75B | 45.04B | 10.59B | -2.28B | 11.71 |
![]()
NVO
Novo Nordisk Adr
|
86.42 | 383.62B | 42.09B | 14.65B | 10.11B | 3.2833 |
![]()
JNJ
Johnson Johnson
|
153.12 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
![]()
ABBV
Abbvie Inc
|
190.60 | 338.37B | 56.33B | 4.28B | 15.62B | 2.40 |
![]()
MRK
Merck Co Inc
|
87.28 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2024-12-16 | Herabstufung | Stifel | Buy → Hold |
2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
2024-11-18 | Herabstufung | Needham | Buy → Hold |
2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
2024-11-14 | Eingeleitet | Citigroup | Neutral |
2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
2024-02-14 | Bestätigt | Needham | Buy |
2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2024-01-24 | Herabstufung | UBS | Buy → Neutral |
2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2023-09-06 | Eingeleitet | HSBC Securities | Buy |
2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
2023-07-24 | Bestätigt | UBS | Buy |
2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
2022-10-13 | Hochstufung | Stifel | Hold → Buy |
2022-10-07 | Hochstufung | Argus | Hold → Buy |
2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2022-03-08 | Herabstufung | Stifel | Buy → Hold |
2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2022-02-04 | Bestätigt | Barclays | Equal Weight |
2022-02-04 | Bestätigt | BofA Securities | Neutral |
2022-02-04 | Bestätigt | Cowen | Outperform |
2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
2022-02-04 | Bestätigt | Needham | Buy |
2022-02-04 | Bestätigt | Oppenheimer | Outperform |
2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
2022-02-04 | Bestätigt | Wedbush | Neutral |
2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
2021-12-06 | Eingeleitet | Goldman | Neutral |
2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
2021-09-23 | Eingeleitet | Needham | Buy |
2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
2021-06-14 | Bestätigt | Truist | Buy |
2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
2021-06-10 | Hochstufung | UBS | Neutral → Buy |
2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
2021-06-08 | Bestätigt | Barclays | Equal Weight |
2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
2021-06-08 | Bestätigt | Jefferies | Buy |
2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
2021-06-08 | Bestätigt | Stifel | Buy |
2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
2021-01-29 | Hochstufung | Stifel | Hold → Buy |
2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2020-10-28 | Eingeleitet | UBS | Neutral |
2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
2020-02-27 | Eingeleitet | Barclays | Overweight |
2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen Inc. (NASDAQ:BIIB) Shares Bought by Retirement Systems of Alabama - MarketBeat
Biogen FY2024 EPS Estimate Decreased by Cantor Fitzgerald - MarketBeat
North Growth Management Ltd. Boosts Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Entropy Technologies LP Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (BIIB) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Why Biogen Inc. (BIIB) Is Among the Best Healthcare Stocks To Buy According to Analysts - Yahoo Finance
Biogen Inc. (NASDAQ:BIIB) Stake Boosted by Mirae Asset Global Investments Co. Ltd. - MarketBeat
Greenleaf Trust Has $775,000 Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Win Advisors Inc. Buys New Shares in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (BIIB) to Release Earnings on Tuesday - MarketBeat
12 Best Healthcare Stocks to Buy According to Analysts - Insider Monkey
As US Sales of Leqembi Lag, Eisai Eyes SubQ Approvals - BioSpace
Seeking Clues to Biogen (BIIB) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics - Yahoo Finance
IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug - MSN
Cantor Fitzgerald cuts Biogen stock price target to $206 By Investing.com - Investing.com South Africa
Cantor Fitzgerald cuts Biogen stock price target to $206 - Investing.com
Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Old North State Wealth Management LLC - MarketBeat
abrdn plc Reduces Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Judge Explains Biogen Class Cert. Ruling After 1st Circ. Order - Law360
Global Water Flavouring Drops Market Poised for Substantial Growth, Projected to Reach USD 73.91 Billion by 2035 | Future Market Insights, Inc. - GlobeNewswire Inc.
Biogen Inc. (NASDAQ:BIIB) Shares Sold by China Universal Asset Management Co. Ltd. - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Forsta AP Fonden - MarketBeat
FY2025 EPS Estimates for Biogen Lowered by Leerink Partnrs - MarketBeat
Sumitomo Life Insurance Co. Trims Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Cairn Investment Group Inc. Sells 3,153 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
One week after Netherlands defeat Biogen takes the win in Germany - JUVE Patent
BRIEF—EC calls for update on regulatory review of lecanemab - The Pharma Letter
Robeco Institutional Asset Management B.V. Has $62.43 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Tardive Dyskinesia Treatment Market Report Analysis - openPR
(BIIB) Investment Analysis and Advice - Stock Traders Daily
FY2027 EPS Estimates for Biogen Reduced by Leerink Partnrs - MarketBeat
Why Are Analysts Bullish on Biogen Inc. (BIIB) Now? - MSN
Smith Group Asset Management LLC Purchases New Shares in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
12 Best S&P 500 Stocks to Invest in According to Analysts - Insider Monkey
Kirr Marbach & Co. LLC IN Sells 4,578 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Citigroup Has Lowered Expectations for Biogen (NASDAQ:BIIB) Stock Price - MarketBeat
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union - GlobeNewswire
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Leqembi review stalls again at European regulator - BioWorld Online
Biogen Stock Price | BIIB Stock Quote, News, and History - Markets Insider
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok - Benzinga
Europe to review safety data for Eisai-Biogen Alzheimer's drug - Reuters
Biogen, Eisai Say EU Panel Set to Discuss Additional Safety Data on Lecanemab -January 31, 2025 at 08:10 am EST - Marketscreener.com
EU to Weigh New Safety Data on Biogen, Eisai Alzheimer’s Drug - Bloomberg
Europe to review safety data for Eisai-Biogen Alzheimer’s drug - 1470 & 100.3 WMBD
Biogen, Eisai: EC Asks CHMP to Take Another Look at Leqembi - MarketWatch
Biogen stock in focus as Alzheimer’s drug review delayed (BIIB) - Seeking Alpha
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):